Dianthus Therapeutics, Inc. (NASDAQ:DNTH - Get Free Report) has been given a consensus recommendation of "Buy" by the nine research firms that are presently covering the stock, MarketBeat reports. Seven analysts have rated the stock with a buy recommendation and two have assigned a strong buy recommendation to the company. The average 12-month target price among brokerages that have issued ratings on the stock in the last year is $46.83.
Several research firms recently weighed in on DNTH. TD Cowen began coverage on shares of Dianthus Therapeutics in a report on Friday, December 20th. They set a "buy" rating on the stock. Oppenheimer boosted their price target on Dianthus Therapeutics from $48.00 to $52.00 and gave the stock an "outperform" rating in a research report on Monday, November 11th. HC Wainwright reiterated a "buy" rating and set a $40.00 price objective on shares of Dianthus Therapeutics in a research note on Monday, November 11th. Finally, Raymond James upgraded shares of Dianthus Therapeutics to a "moderate buy" rating in a research note on Thursday, December 12th.
Read Our Latest Stock Analysis on DNTH
Institutional Trading of Dianthus Therapeutics
Hedge funds and other institutional investors have recently made changes to their positions in the stock. R Squared Ltd bought a new position in Dianthus Therapeutics during the 4th quarter valued at $26,000. Quest Partners LLC lifted its position in shares of Dianthus Therapeutics by 112,400.0% during the third quarter. Quest Partners LLC now owns 1,125 shares of the company's stock worth $31,000 after purchasing an additional 1,124 shares during the last quarter. KLP Kapitalforvaltning AS acquired a new position in Dianthus Therapeutics in the fourth quarter worth about $33,000. KBC Group NV acquired a new position in Dianthus Therapeutics in the fourth quarter worth about $35,000. Finally, BNP Paribas Financial Markets bought a new stake in Dianthus Therapeutics in the fourth quarter valued at about $59,000. Institutional investors own 47.53% of the company's stock.
Dianthus Therapeutics Price Performance
DNTH stock traded up $0.46 during midday trading on Friday, reaching $24.95. 51,067 shares of the company's stock traded hands, compared to its average volume of 246,504. Dianthus Therapeutics has a fifty-two week low of $18.34 and a fifty-two week high of $33.77. The business has a 50-day moving average price of $22.93 and a two-hundred day moving average price of $25.58. The company has a market capitalization of $738.52 million, a P/E ratio of -9.98 and a beta of 1.72.
About Dianthus Therapeutics
(
Get Free ReportDianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.
Featured Articles
Before you consider Dianthus Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Dianthus Therapeutics wasn't on the list.
While Dianthus Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
